Study Stopped
enrolment temporariliy stopped for budget considerations
Evolution of the Therapeutic Care in Ovarian Cancer From 2011
ESME OC
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database : Evolution of the Therapeutic Care in Ovarian Cancer Across the French Comprehensive Cancer Centers From 2011
1 other identifier
observational
13,331
1 country
20
Brief Summary
The ESME Ovarian Cancer database is a multi-center real life database using a retrospective data collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites). This database compiles data from existing data available from patient's electronic medical records (EMR).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2017
Longer than P75 for all trials
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2017
CompletedFirst Submitted
Initial submission to the registry
June 27, 2017
CompletedFirst Posted
Study publicly available on registry
September 7, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedApril 23, 2025
March 1, 2025
2.8 years
June 27, 2017
April 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Describe the evolution of therapeutic care in ovarian cancer across the French comprehensive cancer centers
Patient characteristics, tumor characteristics and treatment patterns
baseline
Secondary Outcomes (1)
Describe the impact of therapeutic strategies on survival criteria
From date of diagnosis or first treatment until the date of date of death from any cause. Follow up until 2022.
Other Outcomes (1)
Describe the impact of therapeutic strategies on survival criteria
From date of diagnosis or first treatment until the date of first documented progression or date of death from any cause. Follow up until 2022.
Study Arms (1)
Ovarian cancer cohort
Any female treated for ovarian cancer in a French comprehensive cancer centers
Eligibility Criteria
All consecutive females treated for an ovarian cancer in a French Comprehensive Cancer Center over the selection period.
You may qualify if:
- years old female
- Female who received surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, diagnostic procedure, other specific therapeutic procedure) for ovarian cancer in a French Comprehensive Cancer Center.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UNICANCERlead
Study Sites (20)
Institut de Cancérologie de l'Ouest - Paul Papin
Angers, 49933, France
Institut Bergonié
Bordeaux, 33076, France
Centre François Baclesse
Caen, 14076, France
Centre Jean Perrin
Clermont-Ferrand, 63011, France
Centre Georges-François Leclerc
Dijon, 21079, France
Centre Oscar Lambret
Lille, 59020, France
Centre Léon Bérard
Lyon, 69373, France
Institut Paoli-Calmettes
Marseille, 13273, France
Institut régional du Cancer Montpellier / Val d'Aurelle
Montpellier, 34298, France
Institut de Cancérologie de Lorraine
Nancy, 54511, France
Institut de cancérologie de l'Ouest - René Gauducheau
Nantes, 44805, France
Centre Antoine Lacassagne
Nice, 06189, France
Institut Curie
Paris, 75005, France
Institut Jean Godinot
Reims, 51056, France
Centre Eugène Marquis
Rennes, 35042, France
Centre Henri Becquerel
Rouen, 76038, France
Institut Curie - Hôpital René Huguenin
Saint-Cloud, 92210, France
Centre Paul Strauss
Strasbourg, 67065, France
Institut Claudius Regaud
Toulouse, 31059, France
Institut Gustave Roussy
Villejuif, 94805, France
Related Publications (7)
Romeo, C, P Meeus, M Rodrigues, E Leblanc, A Floquet, P Pautier, F Marchal, et al. " EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment ". In ePoster, A513.3-A513. BMJ Publishing Group Ltd, 2019. https://doi.org/10.1136/ijgc-2019-ESGO.1013.
RESULTDe Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecol Oncol. 2021 Oct;163(1):64-71. doi: 10.1016/j.ygyno.2021.07.019. Epub 2021 Jul 19.
PMID: 34294414RESULTRodrigues M, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Provensal Gross M, Leblac E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Courtinard C, Gladieff L. Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France. ESMO Congress, September 16-21, 2021 [ePoster 746P] DOI:https://doi.org/10.1016/j.annonc.2021.08.1188
RESULTThomas QD, Boussere A, Classe JM, Pomel C, Costaz H, Rodrigues M, Ray-Coquard I, Gladieff L, Rouzier R, Rouge TM, Gouy S, Barranger E, Sabatier R, Floquet A, Marchal F, Guillemet C, Polivka V, Martin AL, Colombo PE, Fiteni F. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecol Oncol. 2022 Oct;167(1):11-21. doi: 10.1016/j.ygyno.2022.08.005. Epub 2022 Aug 13.
PMID: 35970603RESULTBini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F. Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database. Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040.
PMID: 36011033RESULTBrouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevrier M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M. Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse. Int J Gynecol Cancer. 2023 Apr 3;33(4):577-584. doi: 10.1136/ijgc-2022-003993.
PMID: 36631150RESULTRippstein N, Zemmour C, Rodrigues M, Ray-Coquard I, Gladieff L, Pautier P, Frenel JS, Costaz H, Lebreton C, Pomel C, Colombo PE, Marchal F, Guillemet C, de la Motte Rouge T, Eberst L, Bosquet L, Deluche E, Sabatier R. PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. Oncologist. 2025 May 8;30(5):oyaf075. doi: 10.1093/oncolo/oyaf075.
PMID: 40349134DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 27, 2017
First Posted
September 7, 2017
Study Start
April 1, 2017
Primary Completion
December 31, 2019
Study Completion
December 31, 2025
Last Updated
April 23, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share
In accordance with ethical and legal requirements related to the ESME Data Warehouse, individual data from the ESME databases cannot be made available outside Unicancer secured servers.